BC
BCAX.US Bicara Therapeutics Inc. Common Stock
- Market cap
- USD 665M
- P/E
- -
- P/B
- 1.64x
- ROE
- -59.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is BCAX.US undervalued?
Graham numberThe Graham number of Bicara Therapeutics Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Bicara Therapeutics Inc. Common Stock fundamental analysis
No fundamental analysis for Bicara Therapeutics Inc. Common Stock yet.
Bicara Therapeutics Inc. Common Stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Bicara Therapeutics Inc. Common Stock
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.
Full company profileBicara Therapeutics Inc. Common Stock financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Bicara Therapeutics Inc. Common Stock annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -10.0K | -19.0K | -56.0K | - | - |
| Operating Income | -37.7M | -39.9M | -82.4M | -156M | -261M |
| EBITDA | -37.7M | -52.0M | -67.8M | -138M | -243M |
| Net Income | -37.8M | -52.0M | -68.0M | -138M | -244M |
| EPS | -0.73 | -1.00 | -1.25 | -2.52 | -3.57 |
| Balance Sheet | |||||
| Total Assets | 6.70M | 234M | 510M | 431M | 461M |
| Total Liabilities | 24.0M | 15.5M | 18.1M | 29.5M | 51.2M |
| Shareholders' Equity | -17.3M | 219M | 492M | 401M | 409M |
| Cash & Short-term Investments | 4.16M | 230M | 490M | 415M | 442M |
| Total Debt | - | 657K | 738K | 1.71M | 880K |
| Cash Flow | |||||
| Operating Cash Flow | -32.1M | -45.6M | -74.8M | -107M | -184M |
| Capital Expenditure | 192K | 586K | 71.0K | 280K | 1.04M |
| Free Cash Flow | -32.3M | -46.2M | -74.8M | -107M | -185M |
| Ratios | |||||
| ROE | - | -23.8% | -13.8% | -34.4% | -59.6% |
| ROA | -564.6% | -22.2% | -13.3% | -32.0% | -52.9% |
| Debt to Equity | - | 0.00x | 0.00x | 0.00x | 0.00x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Bicara Therapeutics Inc. Common Stock dividends
Bicara Therapeutics Inc. Common Stock has not paid dividends in the last 4 fiscal years.
Who owns Bicara Therapeutics Inc. Common Stock
- Insiders 10.04%
- Institutions 89.97%
- Public & others 0.00%
- Shares outstanding 66.4M
- Free float 37.1M
Top funds holding BCAX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 1.68M | 2.53% | 0.00% | Sep 2026 |
| State Street® SPDR® S&P® Biotech ETF | 1.17M | 1.77% | +2.68% | Oct 2026 |
| iShares Russell 2000 ETF | 1.11M | 1.68% | 0.00% | Oct 2026 |
| T. Rowe Price Small-Cap Stock | 974K | 1.47% | -39.32% | Sep 2026 |
| Fidelity Select Biotechnology | 902K | 1.36% | -4.54% | Aug 2026 |
| Franklin Biotechnology Discv A(acc)USD | 878K | 1.33% | 0.00% | Sep 2026 |
| Janus Henderson Hrzn Biotec E2 USD | 716K | 1.08% | -1.13% | Jun 2026 |
| Franklin Small Cap Growth Adv | 624K | 0.94% | 0.00% | Sep 2026 |
| T. Rowe Price Integrated US Sm Gr Eq | 569K | 0.86% | -7.12% | Sep 2026 |
| T. Rowe Price Instl Small-Cap Stock | 548K | 0.83% | -37.94% | Sep 2026 |
| JPM Global Healthcare C acc USD | 543K | 0.82% | -3.31% | Sep 2026 |
| T. Rowe Price Health Sciences | 500K | 0.76% | 0.00% | Sep 2026 |
| Fidelity Small Cap Index | 484K | 0.73% | 0.00% | Aug 2026 |
| Franklin Biotechnology Discovery A | 475K | 0.72% | 0.00% | Sep 2026 |
| Belfius Equities Cure C Cap | 373K | 0.56% | +56.34% | Apr 2026 |
| iShares Russell 2000 Growth ETF | 360K | 0.54% | -0.38% | Oct 2026 |
| Franklin Small Cap Value A | 354K | 0.53% | 0.00% | Sep 2026 |
| iShares Biotechnology ETF | 338K | 0.51% | -0.19% | Oct 2026 |
| Columbia Small Cap Growth Inst | 293K | 0.44% | +39.01% | Sep 2026 |
| Vanguard Russell 2000 ETF | 257K | 0.39% | +1.23% | Sep 2026 |
Top institutions holding BCAX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| RA Capital Management, LLC | 7.26M | 10.97% | 0.00% | Jun 2026 |
| T. Rowe Price Investment Management,Inc. | 6.34M | 9.58% | -4.05% | Jun 2026 |
| Siren, L.L.C. | 5.60M | 8.47% | -3.45% | Jun 2026 |
| Vestal Point Capital LP | 5.25M | 7.93% | -3.23% | Jun 2026 |
| Deep Track Capital, LP | 4.10M | 6.20% | +0.92% | Jun 2026 |
| BlackRock Inc | 3.85M | 5.82% | +35.32% | Jun 2026 |
| Jupiter Topco LLC | 3.17M | 4.79% | 0.00% | Jun 2026 |
| TPG GP A, LLC | 3.01M | 4.55% | 0.00% | Jun 2026 |
| Red Tree Management, LLC | 2.92M | 4.41% | -7.68% | Sep 2026 |
| Vanguard Capital Management, LLC | 2.22M | 3.35% | +24.94% | Jun 2026 |
| State Street Corp | 2.05M | 3.10% | +44.35% | Jun 2026 |
| Franklin Templeton Inc | 1.95M | 2.95% | +20.37% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 1.90M | 2.88% | +38.37% | Jun 2026 |
| FMR Inc | 1.89M | 2.86% | -9.89% | Jun 2026 |
| Omega Fund Management LLC | 1.82M | 2.75% | -23.83% | Jun 2026 |
| Geode Capital Management, LLC | 1.16M | 1.76% | +39.92% | Jun 2026 |
| JPMorgan Chase & Co | 1.02M | 1.54% | +472.67% | Jun 2026 |
| Jones Hill Capital LP | 893K | 1.35% | -29.16% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 657K | 0.99% | +42.27% | Sep 2026 |
| Aisling Capital Management LP | 569K | 0.86% | 0.00% | Jun 2026 |
Bicara Therapeutics Inc. Common Stock company profile
- Company name
- Bicara Therapeutics Inc. Common Stock
- Ticker
- BCAX.US
- Exchange
- USA Stocks
- Listed since
- Sep 13, 2024
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 103
- Fiscal year end
- December
- Address
- 116 Huntington Avenue, Boston, MA, United States, 02116
- Phone
- 617 468 4219
- Website
- bicara.com
About Bicara Therapeutics Inc. Common Stock
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.
Bicara Therapeutics Inc. Common Stock management
10- Dr. Claire Mazumdar Clemon M.B.A., Ph.D.CEO & Director · born 1989
- Mr. Ryan Cohlhepp Pharm.D.President, COO & Director · born 1977
- Ms. Jennifer LarsonCFO, Treasurer & Principal Accounting Officer · born 1975
- Ms. Rachel FrankVice President of Investor Relations and Corporate Communications
- Ms. Lara S. Meisner J.D.Chief Legal Officer, Compliance Officer & Corporate Secretary · born 1972
- Ms. Pauline DufresneChief People Officer
- Ms. Rachel SalazarSVP of R&D Strategy and Operations
- Ms. Sathish Hasige Ph.D.Senior VP and Head of Technical Operations & Supply Chain
- Ms. Angela WindtVP & Head of Regulatory Affairs
- Dr. Jeltje Schulten M.B.A., M.D.Senior Vice President of Clinical & Medical Affairs